Stem cell-based therapies have raised considerable interest to develop regenerative treatment for neurological disorders with high disability. In this review, we focus on recent preclinical and clinical evidence of stem cell therapy in the treatment of degenerative neurological diseases and discuss different cell types, delivery routes and biodistribution of stem cell therapy. In addition, recent advances of mechanistic insights of stem cell therapy, including functional replacement by exogenous cells, immunomodulation and paracrine effects of stem cell therapies are also demonstrated. Finally, we also highlight the adjunction approaches that has been implemented to augment their reparative function, survival and migration to target specific tissue, including stem cell preconditioning, genetical engineering, co-transplantation and combined therapy.
LindvallORehncronaSBrundinP, et al.
Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease: a detailed account of methodology and a 6-Month follow-up. Arch Neurol1989;
46: 615–631.
7.
LiuXJiaX.Neuroprotection of stem cells against ischemic brain injury: from bench to clinic. Transl Stroke Res2024;
15: 691–713.
8.
KawaboriMShichinoheHKurodaS, et al.
Clinical trials of stem cell therapy for cerebral ischemic stroke. Int J Mol Sci2020;
21: 7380.
9.
GennaiSMonselAHaoQ, et al.
Cell-based therapy for traumatic brain injury. Br J Anaesth2015;
115: 203–212.
10.
ParmarMGrealishSHenchcliffeC.The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci2020;
21: 103–115.
11.
WangFSunZPengD, et al.
Cell-therapy for Parkinson’s disease: a systematic review and meta-analysis. J Transl Med2023;
21: 601.
12.
ParishCLThompsonLH.Embryonic stem cells go from bench to bedside for Parkinson’s disease. Cell Rep Med2021;
2: 100251.
13.
WangZ-BWangZ-TSunY, et al.
The future of stem cell therapies of Alzheimer’s disease. Ageing Res Rev2022;
80: 101655.
14.
LinT-JChengK-CWuL-Y, et al.
Potential of cellular therapy for ALS: current strategies and future prospects. Front Cell Dev Biol2023;
11: 1292681.
15.
SmithJANicaiseAMIonescuR-B, et al.
Stem cell therapies for progressive multiple sclerosis. Front Cell Dev Biol2021;
9: 696434.
16.
SongC-GZhangY-ZWuH-N, et al.
Stem cells: a promising candidate to treat neurological disorders. Neural Regen Res2018;
13: 1294–1304.
17.
NguyenHZarrielloSCoatsA, et al.
Stem cell therapy for neurological disorders: a focus on aging. Neurobiol Dis2019;
126: 85–104.
18.
TakahashiKTanabeKOhnukiM, et al.
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell2007;
131: 861–872.
19.
TakahashiKYamanakaS.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006;
126: 663–676.
20.
Stoddard-BennettTReijo PeraR.Treatment of Parkinson’s disease through personalized medicine and induced pluripotent stem cells. Cells2019;
8: 26.
HallettPJDeleidiMAstradssonA, et al.
Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell2015;
16: 269–274.
23.
LiuZCheungH-H.Stem Cell-Based therapies for Parkinson disease. Int J Mol Sci2020;
21: 8060.
UllahISubbaraoRBRhoGJ.Human mesenchymal stem cells – current trends and future prospective. Biosci Rep2015;
35: e00191.
27.
AndrzejewskaADabrowskaSLukomskaB, et al.
Mesenchymal stem cells for neurological disorders. Adv Sci (Weinh)2021;
8: 2002944.
28.
HoangDMPhamPTBachTQ, et al.
Stem cell-based therapy for human diseases. Signal Transduct Target Ther2022;
7: 272.
29.
IsakovićJŠererKBarišićB, et al.
Mesenchymal stem cell therapy for neurological disorders: the light or the dark side of the force?Front Bioeng Biotechnol2023;
11: 1139359.
30.
LiauLLLooiQHChiaWC, et al.
Treatment of spinal cord injury with mesenchymal stem cells. Cell Biosci2020;
10: 112.
31.
ChenW-CLiuW-FBaiY-Y, et al.
Transplantation of mesenchymal stem cells for spinal cord injury: a systematic review and network meta-analysis. J Transl Med2021;
19: 178.
32.
CudkowiczMELindborgSRGoyalNA, et al.
A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve2022;
65: 291–302.
33.
TangYYuPChengL.Current progress in the derivation and therapeutic application of neural stem cells. Cell Death Dis2017;
8: e3108.
34.
PluchinoSSmithJAPeruzzotti-JamettiL.Promises and limitations of neural stem cell therapies for progressive multiple sclerosis. Trends Mol Med2020;
26: 898–912.
35.
BonnefontJVanderhaeghenP.Neuronal fate acquisition and specification: time for a change. Curr Opin Neurobiol2021;
66: 195–204.
36.
GageFHTempleS.Neural stem cells: generating and regenerating the brain. Neuron2013;
80: 588–601.
GoutmanSABrownMBGlassJD, et al.
Long-term phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol2018;
5: 730–740.
39.
GlassJDHertzbergVSBoulisNM, et al.
Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology2016;
87: 392–400.
40.
MazziniLGelatiMProficoDC, ALS-NSCs Trial Study Groupet al.
Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl Med2019;
8: 887–897.
41.
BalohRHJohnsonJPAvalosP, et al.
Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial. Nat Med2022;
28: 1813–1822.
42.
FanYShenFFrenzelT, et al.
Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol2010;
67: 488–497.
43.
FangJGuoYTanS, et al.
Autologous endothelial progenitor cells transplantation for acute ischemic stroke: a 4-year follow-up study. Stem Cells Transl Med2019;
8: 14–21.
44.
HessDCAbeTHillWD, et al.
Hematopoietic origin of microglial and perivascular cells in brain. Exp Neurol2004;
186: 134–144.
45.
MuraroPAMartinRMancardiGL, et al.
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol2017;
13: 391–405.
46.
MillerAEChitnisTCohenBA, et al.
Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society. JAMA Neurol2021;
78: 241–246.
47.
BoffaGSignoriAMassacesiL, et al.
Hematopoietic stem cell transplantation in people with active secondary progressive multiple sclerosis. Neurology2023;
100: e1109–e1122.
48.
SudaSNitoCYokoboriS, et al.
Recent advances in cell-based therapies for ischemic stroke. Int J Mol Sci2020;
21: 6718.
49.
MonicheFCabezas-RodriguezJAValverdeR, et al.
Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial. Lancet Neurol2023;
22: 137–146.
50.
GronthosSMankaniMBrahimJ, et al.
Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A2000;
97: 13625–13630.
51.
PierdomenicoLBonsiLCalvittiM, et al.
Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. Transplantation2005;
80: 836–842.
52.
SowaKNitoCNakajimaM, et al.
Impact of dental pulp stem cells overexpressing hepatocyte growth factor after cerebral ischemia/reperfusion in rats. Mol Ther Methods Clin Dev2018;
10: 281–290.
53.
WenceslauCVde SouzaDMMambelli-LisboaNC, et al.
Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington’s disease 3-NP rat model. Cells2022;
11: 1664.
54.
SunTMaQ-H.Repairing neural injuries using human umbilical cord blood. Mol Neurobiol2013;
47: 938–945.
55.
FischerUMHartingMTJimenezF, et al.
Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev2009;
18: 683–692.
56.
EhrhartJDarlingtonDKuzmin-NicholsN, et al.
Biodistribution of infused human umbilical cord blood cells in Alzheimer’s Disease-Like murine model. Cell Transplant2016;
25: 195–199.
57.
ParkB-NLimTSYoonJ-K, et al.
In vivo tracking of intravenously injected mesenchymal stem cells in an Alzheimer’s animal model. Cell Transplant2018;
27: 1203–1209.
58.
OhtaYHamaguchiAOotakiM, et al.
Intravenous infusion of adipose-derived stem/stromal cells improves functional recovery of rats with spinal cord injury. Cytotherapy2017;
19: 839–848.
59.
KimSMJeongCHWooJS, et al.
In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution. Int J Nanomedicine2016;
11: 13–23.
60.
Rosado-de-CastroPHSchmidtFRBattistellaV, et al.
Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients. Regen Med2013;
8: 145–155.
61.
ArgibayBTrekkerJHimmelreichU, et al.
Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia. Sci Rep2017;
7: 40758.
62.
CaoMMaoJDuanX, et al.
In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging. Int J Cancer2018;
142: 1033–1046.
63.
CerriSGrecoRLevandisG, et al.
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects. Stem Cells Transl Med2015;
4: 1073–1085.
64.
SilachevDNKondakovAKZnamenskiiIA, et al.
The use of technetium-99m for intravital tracing of transplanted multipotent stromal cells. Bull Exp Biol Med2016;
162: 153–159.
65.
KawaboriMTanimoriAKittaS, et al.
Evaluation of novel stereotactic cannula for stem cell transplantation against central nervous system disease. Stem Cells Int2020;
2020: 4085617–4085618.
66.
ParkT-YJeonJLeeN, et al.
Co-transplantation of autologous treg cells in a cell therapy for Parkinson’s disease. Nature2023;
619: 606–615.
67.
SchoeberleinAMuellerMReinhartU, et al.
Homing of placenta-derived mesenchymal stem cells after perinatal intracerebral transplantation in a rat model. Am J Obstet Gynecol2011;
205: 277.e1–277.e6.
68.
CuiL-LGolubczykDTolppanenA-M, et al.
Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy?Ann Neurol2019;
86: 5–16.
69.
KimHNaDLLeeNK, et al.
Intrathecal injection in a rat model: a potential route to deliver human Wharton’s jelly-derived mesenchymal stem cells into the brain. Int J Mol Sci2020;
21: 1272.
70.
NakanishiMWatanabeYHondaN, et al.
Dynamics of host and graft after cell sheet transplantation: basic study for the application of amyotrophic lateral sclerosis. Brain Res2019;
1724: 146444.
71.
OhK-WNohM-YKwonM-S, et al.
Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol2018;
84: 361–373.
72.
SykováERychmachPDrahorádováI, et al.
Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial. Cell Transplant2017;
26: 647–658.
73.
CroweTPGreenleeMHWKanthasamyAG, et al.
Mechanism of intranasal drug delivery directly to the brain. Life Sci2018;
195: 44–52.
74.
LiY-HYuJ-ZLiuC-Y, et al.
Intranasal delivery of FSD-C10, a novel rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis. Immunology2014;
143: 219–229.
75.
DanielyanLBeer-HammerSStolzingA, et al.
Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant2014;
23 Suppl 1: S123–139.
76.
SalamaMSobhMEmamM, et al.
Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease. Exp Ther Med2017;
13: 976–982.
77.
JjLDjWMeP, et al. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. PubMedhttps://pubmed.ncbi.nlm.nih.gov/25492117/ (accessed 31 Jul 2024).
78.
SanaiNTramontinADQuiñones-HinojosaA, et al.
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature2004;
427: 740–744.
79.
CvBJyL, FD, et al. Nose-to-brain delivery of stem cells in stroke: the role of extracellular vesicles. PubMed, https://pubmed.ncbi.nlm.nih.gov/39401332/ (2024, accessed 26 November 2024).
80.
ZhangY-THeK-JZhangJ-B, et al.
Advances in intranasal application of stem cells in the treatment of central nervous system diseases. Stem Cell Res Ther2021;
12: 210.
81.
AndresRHHorieNSlikkerW, et al.
Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain2011;
134: 1777–1789.
82.
ChuKKimMJeongS-W, et al.
Human neural stem cells can migrate, differentiate, and integrate after intravenous transplantation in adult rats with transient forebrain ischemia. Neurosci Lett2003;
343: 129–133.
83.
RedmondDEBjugstadKBTengYD, et al.
Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A2007;
104: 12175–12180.
84.
JiangPChenCLiuX-B, et al.
Human iPSC-Derived immature astroglia promote oligodendrogenesis by increasing TIMP-1 secretion. Cell Rep2016;
15: 1303–1315.
85.
LlorenteILXieYMazzitelliJA, et al.
Patient-derived glial enriched progenitors repair functional deficits due to white matter stroke and vascular dementia in rodents. Sci Transl Med2021;
13: eaaz6747.
86.
HwangJWLeeNKYangJH, et al.
A comparison of immune responses exerted following syngeneic, allogeneic, and xenogeneic transplantation of mesenchymal stem cells into the mouse brain. Int J Mol Sci2020;
21: 3052.
87.
CoyneTMMarcusAJReynoldsK, et al.
Disparate host response and donor survival after the transplantation of mesenchymal or neuroectodermal cells to the intact rodent brain. Transplantation2007;
84: 1507–1516.
88.
EinsteinOFainsteinNVakninI, et al.
Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol2007;
61: 209–218.
89.
LeeRHPulinAASeoMJ, et al.
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell2009;
5: 54–63.
90.
YangBHamiltonJAValenzuelaKS, et al.
Multipotent adult progenitor cells enhance recovery after stroke by modulating the immune response from the spleen. Stem Cells2017;
35: 1290–1302.
91.
MaysRWSavitzSI.Intravenous cellular therapies for acute ischemic stroke. Stroke2018;
49: 1058–1065.
92.
AcostaSATajiriNHooverJ, et al.
Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke2015;
46: 2616–2627.
93.
XuKLeeJ-YKanekoY, et al.
Human stem cells transplanted into the rat stroke brain migrate to the spleen via lymphatic and inflammation pathways. Haematologica2019;
104: 1062–1073.
94.
VigoTVoulgari-KokotaAErredeM, et al.
Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes. Glia2021;
69: 1204–1215.
95.
LuuNTMcgettrickHMBuckleyCD, et al.
Crosstalk between mesenchymal stem cells and endothelial cells leads to downregulation of cytokine-induced leukocyte recruitment. Stem Cells2013;
31: 2690–2702.
96.
MengeTZhaoYZhaoJ, et al.
Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med2012;
4: 161ra150.
97.
GiriJDasRNylenE, et al.
CCL2 and CXCL12 derived from mesenchymal stromal cells cooperatively polarize IL-10+ tissue macrophages to mitigate gut injury. Cell Rep2020;
30: 1923–1934.e4.
98.
YangFLiW-BQuY-W, et al.
Bone marrow mesenchymal stem cells induce M2 microglia polarization through PDGF-AA/MANF signaling. World J Stem Cells2020;
12: 633–658.
99.
MalekpourKHazratiASoudiS, et al.
Mechanisms behind therapeutic potentials of mesenchymal stem cell mitochondria transfer/delivery. J Control Release2023;
354: 755–769.
100.
TanYLEngSPHafezP, et al.
Mesenchymal stromal cell mitochondrial transfer as a cell rescue strategy in regenerative medicine: a review of evidence in preclinical models. Stem Cells Transl Med2022;
11: 814–827.
101.
LiuKGuoLZhouZ, et al.
Mesenchymal stem cells transfer mitochondria into cerebral microvasculature and promote recovery from ischemic stroke. Microvasc Res2019;
123: 74–80.
102.
LiuWTangPWangJ, et al.
Extracellular vesicles derived from melatonin-preconditioned mesenchymal stem cells containing USP29 repair traumatic spinal cord injury by stabilizing NRF2. J Pineal Res2021;
71: e12769.
103.
BernstockJDPeruzzotti-JamettiLYeD, et al.
Neural stem cell transplantation in ischemic stroke: a role for preconditioning and cellular engineering. J Cereb Blood Flow Metab2017;
37: 2314–2319.
104.
OthmanFATanSC.Preconditioning strategies to enhance neural stem cell-based therapy for ischemic stroke. Brain Sci2020;
10: 893.
105.
WakaiTNarasimhanPSakataH, et al.
Hypoxic preconditioning enhances neural stem cell transplantation therapy after intracerebral hemorrhage in mice. J Cereb Blood Flow Metab2016;
36: 2134–2145.
106.
TianHYangXZhaoJ, et al.
Hypoxia-preconditioned bone marrow mesenchymal stem cells improved cerebral collateral circulation and stroke outcome in mice. Arterioscler Thromb Vasc Biol2023;
43: 1281–1294.
WulansariNKimE-HSulistioYA, et al.
Vitamin C-induced epigenetic modifications in donor NSCs establish midbrain marker expressions critical for cell-based therapy in Parkinson’s disease. Stem Cell Reports2017;
9: 1192–1206.
109.
HuangDCaoYYangX, et al.
A nanoformulation-mediated multifunctional stem cell therapy with improved beta-amyloid clearance and neural regeneration for Alzheimer’s disease. AdvMater 2021;
33: 2006357.
HanHChenB-TLiuY, et al.
Engineered stem cell-based strategy: a new paradigm of next-generation stem cell product in regenerative medicine. J Control Release2024;
365: 981–1003.
112.
KhalinIAlyautdinRWongTW, et al.
Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury. Drug Deliv2016;
23: 3520–3528.
113.
ZhaoM-ZNonoguchiNIkedaN, et al.
Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab2006;
26: 1176–1188.
ShahrorRALinaresGRWangY, et al.
Transplantation of mesenchymal stem cells overexpressing fibroblast growth factor 21 facilitates cognitive recovery and enhances neurogenesis in a mouse model of traumatic brain injury. J Neurotrauma2020;
37: 14–26.
116.
De LuzyIRLawKCLMoriartyN, et al.
Human stem cells harboring a suicide gene improve the safety and standardisation of neural transplants in parkinsonian rats. Nat Commun2021;
12: 3275.
117.
HuangYWangJCaiJ, et al.
Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation. Theranostics2018;
8: 5929–5944.
118.
CuiL-LNitzscheFPryazhnikovE, et al.
Integrin α4 overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection. Stroke2017;
48: 2895–2900.
119.
ChenW-SHuangY-CLiuC-H, et al.
U Pb zircon geochronology constraints on the ages of the tananao schist belt and timing of orogenic events in Taiwan: implications for a new tectonic evolution of the South China block during the mesozoic. Tectonophysics2016;
686: 68–81.
120.
JiangX-CXiangJ-JWuH-H, et al.
Neural stem cells transfected with reactive oxygen species–responsive polyplexes for effective treatment of ischemic stroke. Advanced Materials2019;
31: 1807591.
121.
LiJTangYWangY, et al.
Neurovascular recovery via cotransplanted neural and vascular progenitors leads to improved functional restoration after ischemic stroke in rats. Stem Cell Reports2014;
3: 101–114.
122.
SunKZhouZJuX, et al.
Combined transplantation of mesenchymal stem cells and endothelial progenitor cells for tissue engineering: a systematic review and meta-analysis. Stem Cell Res Ther2016;
7: 151.
123.
QiaoL-YHuangF-JZhaoM, et al.
A Two-Year Follow-Up study of cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells in ischemic stroke patients. Cell Transplant2014;
23 Suppl 1: S65–72.
124.
Kaur G, Thompson LA, Dufour JM, et al. Sertoli cells–immunological sentinels of spermatogenesis. Semin Cell Dev Biol 2014; 30: 36–44.
125.
SanbergPRBorlonganCVSaportaS, et al.
Testis-derived sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nat Biotechnol1996;
14: 1692–1695.
126.
SanbergPRBorlonganCVOthbergAI, et al.
Testis-derived sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats. Nat Med1997;
3: 1129–1132.
127.
IpCWWischhusenJ.Versatile guardians: regenerative regulatory T cells in Parkinson’s disease rodent models. Signal Transduct Target Ther2023;
8: 430.
128.
CaplanHWPrabhakaraKSToledano FurmanNE, et al.
Combination therapy with treg and mesenchymal stromal cells enhances potency and attenuation of inflammation after traumatic brain injury compared to monotherapy. Stem Cells2021;
39: 358–370.
129.
YangFLiuYTuJ, et al.
Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF. Nat Commun2014;
5: 5627.
130.
KirkebyANelanderJHobanDB, et al.
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. Cell Stem Cell2023;
30: 1299–1314.e9.
131.
YangYSongJ-JChoiYR, et al.
Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease. Proc Natl Acad Sci U S A2022;
119: e2110746119.
132.
ZhangY-XYuanM-ZChengL, et al.
Treadmill exercise enhances therapeutic potency of transplanted bone mesenchymal stem cells in cerebral ischemic rats via anti-apoptotic effects. BMC Neurosci2015;
16: 56.
133.
SasakiYSasakiMKataoka-SasakiY, et al.
Synergic effects of rehabilitation and intravenous infusion of mesenchymal stem cells after stroke in rats. Phys Ther2016;
96: 1791–1798.
134.
AkhoundzadehKVakiliASameniHR, et al.
Effects of the combined treatment of bone marrow stromal cells with mild exercise and thyroid hormone on brain damage and apoptosis in a mouse focal cerebral ischemia model. Metab Brain Dis2017;
32: 1267–1277.
135.
GhumanHPerryNGriceL, et al.
Physical therapy exerts sub-additive and suppressive effects on intracerebral neural stem cell implantation in a rat model of stroke. J Cereb Blood Flow Metab2022;
42: 826–843.
136.
DöbrössyMDDunnettSB.The influence of environment and experience on neural grafts. Nat Rev Neurosci2001;
2: 871–879.
137.
MuJBakreenAJuntunenM, et al.
Combined adipose tissue-derived mesenchymal stem cell therapy and rehabilitation in experimental stroke. Front Neurol2019;
10: 235.
138.
ChoS-RSuhHYuJH, et al.
Astroglial activation by an enriched environment after transplantation of mesenchymal stem cells enhances angiogenesis after hypoxic-ischemic brain injury. Int J Mol Sci2016;
17: 1550.
139.
YangCQiuYQingY, et al.
Synergistic effect of electric stimulation and mesenchymal stem cells against Parkinson’s disease. Aging (Albany NY)2020;
12: 16062–16071.
140.
PengJ-JShaRLiM-X, et al.
Repetitive transcranial magnetic stimulation promotes functional recovery and differentiation of human neural stem cells in rats after ischemic stroke. Exp Neurol2019;
313: 1–9.
141.
BarkerRABjörklundAGashDM, et al.
GDNF and Parkinson’s disease: where next? A summary from a recent workshop. J Parkinsons Dis2020;
10: 875–891.
142.
MoriartyNGantnerCWHuntCPJ, et al.
A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell2022;
29: 434–448.e5.
143.
GantnerCWDe LuzyIRKauhausenJA, et al.
Viral delivery of GDNF promotes functional integration of human stem cell grafts in Parkinson’s disease. Cell Stem Cell2020;
26: 511–526.e5.
144.
BalseanuATBugaA-MCatalinB, et al.
Multimodal approaches for regenerative stroke therapies: combination of granulocyte Colony-Stimulating factor with bone marrow mesenchymal stem cells is not superior to G-CSF alone. Front Aging Neurosci2014;
6: 130. https://www.frontiersin.org/articles/10.3389/fnagi.2014.00130 (accessed 16 Jan2024).
145.
BugaA-MScheibeJMollerK, et al.
Granulocyte colony-stimulating factor and bone marrow mononuclear cells for stroke treatment in the aged brain. Curr Neurovasc Res2015;
12: 155–162.
146.
SalemNSalemMYElmaghrabiMM, et al.
Does vitamin C have the ability to augment the therapeutic effect of bone marrow-derived mesenchymal stem cells on spinal cord injury?Neural Regen Res2017;
12: 2050–2058.
147.
LiuDYeYXuL, et al.
Icariin and mesenchymal stem cells synergistically promote angiogenesis and neurogenesis after cerebral ischemia via PI3K and ERK1/2 pathways. Biomed Pharmacother2018;
108: 663–669.
148.
WeiNLiCZhuY, et al.
Fluoxetine regulates the neuronal differentiation of neural stem cells transplanted into rat brains after stroke by increasing the 5HT level. Neurosci Lett2022;
772: 136447.
149.
PiaoJZabierowskiSDuboseBN, et al.
Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell2021;
28: 217–229.e7.
150.
ParkSParkCWEomJH, et al.
Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson’s disease. Cell Stem Cell2024;
31: 25–38.e8.
151.
ChavezMRaneDAChenX, et al.
Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus. Nat Biomed Eng2023;
7: 661–671.
152.
ShibuyaYKumarKKMaderMM-D, et al.
Treatment of a genetic brain disease by CNS-wide microglia replacement. Sci Transl Med2022;
14: eabl9945.
153.
YooYNeumayerGShibuyaY, et al.
A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer’s disease. Cell Stem Cell2023;
30: 1043–1053.e6.
